NDAINTRAVENOUSSOLUTION
Approved
Jan 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NEOSTIGMINE METHYLSULFATE (neostigmine methylsulfate) by Fresenius Kabi is action- neostigmine methylsulfate is a competitive cholinesterase inhibitor. First approved in 2015.
Drug data last refreshed 43m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Neostigmine methylsulfate is a competitive cholinesterase inhibitor administered intravenously as a solution that reverses neuromuscular blockade induced by nondepolarizing agents. By inhibiting acetylcholinesterase, it increases acetylcholine concentration in the synaptic cleft, allowing acetylcholine to compete with and displace neuromuscular blocking agents from their binding sites. This product is used in perioperative settings to restore neuromuscular function at the end of anesthesia.
Peak
Product is in peak lifecycle stage with stable demand in perioperative settings; teams are focused on market maintenance rather than expansion.
Mechanism of Action
Action- Neostigmine methylsulfate is a competitive cholinesterase inhibitor. By reducing the breakdown of acetylcholine, neostigmine methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on neostigmine methylsulfate offers stability in a niche perioperative specialty with direct engagement in hospital and surgery center channels. Professionals can expect focused career growth in hospital-based commercial and medical affairs roles rather than large-scale consumer marketing.
Medical Science Liaison
Worked on NEOSTIGMINE METHYLSULFATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.